We summarize the current state of development for inhibitors against Menin‐KMT2A, DOT1L, KDM1A, and Polycomb complexes, and the arginine methyltransferase PRMT5 for the treatment of myeloid malignancies, lymphoma, and different solid tumors. Here, DOT1L is linked to myeloid neoplasm.